237 related articles for article (PubMed ID: 22712838)
1. Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
Ogura M; Itoh K; Ishizawa K; Kobayashi Y; Tobinai K; Kinoshita T; Hirano M; Ueda R; Shibata T; Nakamura S; Tsukasaki K; Hotta T; Shimoyama M; Morishima Y;
Leuk Lymphoma; 2013 Jan; 54(1):46-52. PubMed ID: 22712838
[TBL] [Abstract][Full Text] [Related]
2. Acute liver failure secondary to ABVD use.
Eslami A; Mathur AD; Jha KK; Wang H
BMJ Case Rep; 2018 Jul; 2018():. PubMed ID: 30061135
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial.
Luminari S; Fossa A; Trotman J; Molin D; d'Amore F; Enblad G; Berkahn L; Barrington SF; Radford J; Federico M; Kirkwood AA; Johnson PWM
J Clin Oncol; 2024 Jan; 42(1):13-18. PubMed ID: 37883739
[No Abstract] [Full Text] [Related]
4. Treatment of Hodgkin Lymphoma With ABVD Chemotherapy in Rural Rwanda: A Model for Cancer Care Delivery Implementation.
DeBoer RJ; Shyirambere C; Driscoll CD; Butera Y; Paciorek A; Ruhangaza D; Fadelu TA; Umwizerwa A; Bigirimana JB; Muhayimana C; Nguyen C; Park PH; Mpunga T; Lehmann L; Shulman LN
JCO Glob Oncol; 2020 Jul; 6():1093-1102. PubMed ID: 32678711
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Bleomycin Deficit on Survival in Hodgkin's Lymphoma Patients: A Retrospective Study.
Soldi LR; Rabelo DH; da Silva PHR; Silva VLC; Silva MJB
Cancer Treat Res Commun; 2024; 38():100790. PubMed ID: 38241969
[TBL] [Abstract][Full Text] [Related]
6. Safety, efficacy, and affordability of ABVD for Hodgkin lymphoma in Malawi: a prospective cohort study.
Mponda M; Kudowa E; Craven DM; Eastburg LC; Chikasema M; Kasonkanji E; Tomoka T; Roush SM; Simwinga L; Mumba N; Gopal S; Fedoriw Y; Painschab MS
EClinicalMedicine; 2024 Mar; 69():102480. PubMed ID: 38356728
[TBL] [Abstract][Full Text] [Related]
7. Outcome in patients with HIV-associated Hodgkin lymphoma treated with chemotherapy using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the combination antiretroviral therapy (cART) era: results of a multicenter study from China.
Xiao L; Wang C; Ma S; Wang Y; Guan L; Wu J; Zhang W; Liu Y; Wu Y
Infect Agent Cancer; 2024 Apr; 19(1):12. PubMed ID: 38622727
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy for Advanced Hodgkin Lymphoma with Initial Bulk: A Combined Analysis of Two Randomized Trials.
Hughes RT; Razavian NB; Shenker RF; Kelsey CR; Smith S; D'Agostino RB; Winkfield KM
Adv Radiat Oncol; 2024 May; 9(5):101450. PubMed ID: 38550369
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Motzer RJ; Escudier B; McDermott DF; George S; Hammers HJ; Srinivas S; Tykodi SS; Sosman JA; Procopio G; Plimack ER; Castellano D; Choueiri TK; Gurney H; Donskov F; Bono P; Wagstaff J; Gauler TC; Ueda T; Tomita Y; Schutz FA; Kollmannsberger C; Larkin J; Ravaud A; Simon JS; Xu LA; Waxman IM; Sharma P;
N Engl J Med; 2015 Nov; 373(19):1803-13. PubMed ID: 26406148
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Puig O; Daniele B; Kudo M; Merle P; Park JW; Ross P; Peron JM; Ebert O; Chan S; Poon TP; Colombo M; Okusaka T; Ryoo BY; Minguez B; Tanaka T; Ohtomo T; Ukrainskyj S; Boisserie F; Rutman O; Chen YC; Xu C; Shochat E; Jukofsky L; Reis B; Chen G; Di Laurenzio L; Lee R; Yen CJ
J Hepatol; 2016 Aug; 65(2):289-95. PubMed ID: 27085251
[TBL] [Abstract][Full Text] [Related]
11. Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma.
Cheng AL; Thongprasert S; Lim HY; Sukeepaisarnjaroen W; Yang TS; Wu CC; Chao Y; Chan SL; Kudo M; Ikeda M; Kang YK; Pan H; Numata K; Han G; Balsara B; Zhang Y; Rodriguez AM; Zhang Y; Wang Y; Poon RT
Hepatology; 2016 Sep; 64(3):774-84. PubMed ID: 27082062
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.
Vergote I; Armstrong D; Scambia G; Teneriello M; Sehouli J; Schweizer C; Weil SC; Bamias A; Fujiwara K; Ochiai K; Poole C; Gorbunova V; Wang W; O'Shannessy D; Herzog TJ
J Clin Oncol; 2016 Jul; 34(19):2271-8. PubMed ID: 27001568
[TBL] [Abstract][Full Text] [Related]
13. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.
Fujitani K; Yang HK; Mizusawa J; Kim YW; Terashima M; Han SU; Iwasaki Y; Hyung WJ; Takagane A; Park DJ; Yoshikawa T; Hahn S; Nakamura K; Park CH; Kurokawa Y; Bang YJ; Park BJ; Sasako M; Tsujinaka T;
Lancet Oncol; 2016 Mar; 17(3):309-318. PubMed ID: 26822397
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of neoadjuvant chemotherapy with S-1 and cisplatin for stage III gastric cancer: KUGC03.
Okabe H; Hata H; Ueda S; Zaima M; Tokuka A; Yoshimura T; Ota S; Kinjo Y; Yoshimura K; Sakai Y;
J Surg Oncol; 2016 Jan; 113(1):36-41. PubMed ID: 26604064
[TBL] [Abstract][Full Text] [Related]
15. An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy.
Noguchi M; Matsumoto K; Uemura H; Arai G; Eto M; Naito S; Ohyama C; Nasu Y; Tanaka M; Moriya F; Suekane S; Matsueda S; Komatsu N; Sasada T; Yamada A; Kakuma T; Itoh K
Clin Cancer Res; 2016 Jan; 22(1):54-60. PubMed ID: 26581246
[TBL] [Abstract][Full Text] [Related]
16. Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701).
Nakanishi K; Kobayashi D; Mochizuki Y; Ishigure K; Ito S; Kojima H; Ishiyama A; Fujitake S; Shikano T; Morita S; Kodera Y
Int J Clin Oncol; 2016 Jun; 21(3):557-65. PubMed ID: 26547424
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of proton beam therapy as a nonsurgical approach for mucosal melanoma of the nasal cavity or para-nasal sinuses.
Zenda S; Akimoto T; Mizumoto M; Hayashi R; Arahira S; Okumura T; Sakurai H
Radiother Oncol; 2016 Feb; 118(2):267-71. PubMed ID: 26547102
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.
Yamazaki N; Kiyohara Y; Uhara H; Fukushima S; Uchi H; Shibagaki N; Tsutsumida A; Yoshikawa S; Okuyama R; Ito Y; Tokudome T
Cancer Chemother Pharmacol; 2015 Nov; 76(5):997-1004. PubMed ID: 26410424
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.
Yamazaki N; Uhara H; Fukushima S; Uchi H; Shibagaki N; Kiyohara Y; Tsutsumida A; Namikawa K; Okuyama R; Otsuka Y; Tokudome T
Cancer Chemother Pharmacol; 2015 Nov; 76(5):969-75. PubMed ID: 26407818
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
